351 related articles for article (PubMed ID: 33257382)
1. Nivolumab for malignant peritoneal mesothelioma.
Tanaka T; Miyamoto Y; Sakai A; Fujimoto N
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257382
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin plus pemetrexed therapy and subsequent immune checkpoint inhibitor administration for malignant peritoneal mesothelioma without pleural lesions: Case report.
Ikushima H; Sakatani T; Ohara S; Takeshima H; Horiuchi H; Morikawa T; Usui K
Medicine (Baltimore); 2020 May; 99(22):e19956. PubMed ID: 32481365
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab activity in advanced refractory malignant peritoneal mesothelioma.
Becker O; Beaulaton C; Masliah-Planchon J; Servois V; Watson S
Eur J Cancer; 2021 Feb; 144():386-388. PubMed ID: 33358840
[No Abstract] [Full Text] [Related]
4. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
5. A case of malignant peritoneal mesothelioma with a Fitz-Hugh-Curtis syndrome-like imaging finding.
Iwadare T; Kimura T; Nagata Y; Suzuki H; Kunimoto H; Kitabatake H; Seki A; Ochi Y; Hara E; Umemura T
Clin J Gastroenterol; 2023 Jun; 16(3):372-376. PubMed ID: 36781827
[TBL] [Abstract][Full Text] [Related]
6. [A case of malignant peritoneal mesothelioma successfully treated with systemic chemothrapy].
Igarashi K; Hayashi M; Sato M; Aiba T; Yoneyama O; Waguri N; Furukawa K; Sugimura K; Shibuya H
Nihon Shokakibyo Gakkai Zasshi; 2012 Mar; 109(3):451-9. PubMed ID: 22398911
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
8. [A case of diffuse peritoneal malignant mesothelioma--intraabdominal administration of cisplatin is useful for diminishing ascites].
Noguchi T; Kawamura M; Kawamura T; Shimamura T; Sasaki K; Hosono T; Sato R; Murakami K
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1975-8. PubMed ID: 20948267
[TBL] [Abstract][Full Text] [Related]
9. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
Fujimoto E; Kijima T; Kuribayashi K; Negi Y; Kanemura S; Mikami K; Doi H; Kitajima K; Nakano T
Expert Rev Anticancer Ther; 2017 Sep; 17(9):865-872. PubMed ID: 28594258
[TBL] [Abstract][Full Text] [Related]
10. Localized biphasic malignant mesothelioma presenting as a giant pelvic wall mass: a rare case report and literature review.
Liu Y; Wu J; Zhao Y; Zhang P; Hua Z; Dong W; Lin T; Liu A
BMC Med Imaging; 2020 May; 20(1):48. PubMed ID: 32375654
[TBL] [Abstract][Full Text] [Related]
11. Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report.
Tang LK; Li ZK; Xiang YL; Ma DY; Du GB
Medicine (Baltimore); 2023 Jul; 102(30):e34349. PubMed ID: 37505161
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Malignant Peritoneal Mesothelioma Treated with Cisplatin and Pemetrexed].
Sone T; Omori S; Hayashi K; Yamato H; Ohira K; Kondo N; Takagi Y; Kato K
Gan To Kagaku Ryoho; 2018 Jun; 45(6):993-995. PubMed ID: 30026430
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund.
Cerbone L; Delfanti S; Crivellari S; De Angelis AM; Mazzeo L; Proto C; Occhipinti M; Lo Russo G; Dellepiane C; Biello F; Alabiso I; Verderame F; Gauna R; De Simone I; Cuppone F; Petraglia S; Pasello G; Ceresoli GL; Garassino MC; Torri V; Grosso F
Tumori; 2024 Jun; 110(3):168-173. PubMed ID: 38372045
[TBL] [Abstract][Full Text] [Related]
14. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
15. [A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin].
Kobayashi M; Moriwaki T; Ochi D; Saito R; Kobayashi K; Sugaya A; Akutsu D; Hamano Y; Imanishi M; Yamamoto Y; Yamada T; Nakano N; Sugano M; Hara K; Hyodo I
Gan To Kagaku Ryoho; 2014 Mar; 41(3):361-4. PubMed ID: 24743284
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
[TBL] [Abstract][Full Text] [Related]
17. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
Yin W; Zheng G; Yang K; Song H; Liang Y
World J Surg Oncol; 2018 Mar; 16(1):44. PubMed ID: 29506546
[TBL] [Abstract][Full Text] [Related]
18. [Malignant Peritoneal Mesothelioma Diagnosed as an Inguinal Mass : A Case Report].
Araki Y; Ikeda M; Iribe Y; Asaoka M; Uemura K; Sano F; Ikeda I
Hinyokika Kiyo; 2021 Oct; 67(10):475-477. PubMed ID: 34742174
[TBL] [Abstract][Full Text] [Related]
19. Diffuse malignant peritoneal mesothelioma.
Shih CA; Ho SP; Tsay FW; Lai KH; Hsu PI
Kaohsiung J Med Sci; 2013 Nov; 29(11):642-5. PubMed ID: 24183360
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal mesothelioma: the site of origin matters.
Kindler HL
Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
